Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1719917 | 0.80 | HTT (0.67) | HTTMAPTKMT2AKDM4EGAA | |
| SCHEMBL9461214 | 0.80 | HTT (0.67) | HTTMAPTKMT2AKDM4EGAA | |
| SCHEMBL2091085 | 0.78 | HTT (1.00) | HTTMAPTKMT2AKDM4EGAA | |
| SCHEMBL8943069 | 0.74 | CYP1A2 (0.46) | HTTMAPTKMT2AKDM4EGAA | |
| SCHEMBL23610343 | 0.71 | HTT (0.55) | HTTMAPTKMT2AKDM4EGAA | |
| SCHEMBL11878004 | 0.70 | HTT (0.64) | HTTMAPTKMT2AGAAMEN1 | |
| SCHEMBL8629160 | 0.69 | HTT (0.53) | HTTMAPTKMT2AKDM4EALDH1A1 | |
| SCHEMBL11981610 | 0.69 | HTT (0.52) | HTTMAPTKMT2AKDM4EGAA | |
| SCHEMBL11290468 | 0.69 | MAPT (0.50) | HTTMAPTKMT2AKDM4EGAA | |
| SCHEMBL9460630 | 0.68 | HTT (0.52) | HTTKMT2AKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11932653-B2 | Lycorine derivative, and pharmaceutical composition and use thereof | SHANDONG DYNE MARINE BIOPHARMACEUTICAL CO., LTD (CN) | 2024-03-19 | — | — | US | disclosed |
| US-20210206777-A1 | LYCORINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANDONG DYNE MARINE BIOPHARMACEUTICAL CO., LTD (CN) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932653-B2 | Lycorine derivative, and pharmaceutical composition and use thereof | LCT, LARP7, LASP1 | HTT 1455/4885MAPT 3750/4885KMT2A 3991/4885 |
| US-20210206777-A1 | LYCORINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | LARP7, LARP1, LASP1 | HTT 1579/4885MAPT 3287/4885KMT2A 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.